Skip to main content

Non-Hispanic Black Melanoma Patients Present With Advanced Disease

Medically reviewed by Carmen Pope, BPharm. Last updated on May 16, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, May 15, 2024 -- Non-Hispanic Black (NHB) melanoma patients have distinct tumor characteristics, presenting with more advanced disease and exhibiting worse outcomes, according to a study published in the May issue of the Journal of Surgical Oncology.

Jessica A. Steadman, M.B.B.S., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined features of melanoma within NHB patients to inform strategies for earlier detection and treatment. Nonmetastatic melanoma patients with known TN category and race were identified from 2004 to 2019 Surveillance, Epidemiology, and End Results data.

Of the 492,597 patients, 0.3 percent were NHB. Compared with non-Hispanic White (NHW) patients, NHB patients were younger (21 versus 17 percent aged younger than 50 years) and were more often female (54 versus 41 percent). The researchers found that lower extremity was the most common site for NHBs (52 versus 15 percent for NHWs); in addition, T category was higher (Tis to T1 and T3 to T4: 55 and 27 percent versus 82 and 8 percent, respectively) and stage at presentation was higher (stage III, 19 versus 6 percent). Among NHB patients, men were older than women and they were more often node-positive. After adjustment for age and clinical node status, five-year stage III cancer-specific survival was 42 percent for NHB men versus 71 percent for women.

"Our contemporary overview of nonmetastatic cutaneous melanoma highlights that NHB patients present with more advanced disease and exhibit inferior outcomes," the authors write. "This is most notable among older male NHB patients."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

Delayed Melanoma Care During Pandemic Proved Costly

TUESDAY, Feb. 27, 2024 -- Delays in melanoma diagnoses due to COVID-19 pandemic lockdowns were associated with a significant burden, including years of life lost and costs...

Amtagvi Approved by the FDA for Treatment of Advanced Melanoma

TUESDAY, Feb. 20, 2024 -- Amtagvi (lifileucel) has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Amtagvi becomes the first...

Smoking Linked to Melanoma-Associated Death in Early-Stage Melanoma

MONDAY, Feb. 12, 2024 -- For patients with clinical stage I and II melanoma, smoking is associated with an increased risk for melanoma-associated death, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.